Arecor and JDRF joint research, development and commercialisation agreement. Arecor Ltd has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organisation
In an article for the New York Times, Donald McNeil reported, “With insulin prices skyrocketing and substantial shortages developing in poorer countries, the World Health
New diabetes treatments can be hard to keep track of. Here we take a look at some of the newer treatments and trials for diabetes.
In a report entitled, Optimal prandial timing of bolus insulin in diabetes management: a review, looked at data from several studies and concluded that taking
Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes. Despite results from 6
Novo Nordisk and Glooko have announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes.
Faster insulin The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA), has recommended marketing authorisation for Novo Nordisk Fiasp
Researchers in an international study have uncovered new genetic evidence of how the benefits of the world’s most commonly used Type 2 diabetes drug may
A glucogen powder now in development by Eli Lilly to treat dangerously low blood sugar in patients with Type 1 diabetes, the goal being to
Novo Nordisk has announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the
